Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436189 · ClinicalTrials.gov registry record · NA
Assess Cancer in Ovarian Tumors With Biomarkers.
A NA study of Ovarian Tumor, sponsored by Ciphergen Biosystems.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 18
- Study locations
NCT00436189: Completed NA study of Ovarian Tumor, sponsored by Ciphergen Biosystems.
NCT00436189 is a NA study of Ovarian Tumor that has completed, run by Ciphergen Biosystems. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436189, a NA study of Ovarian Tumor, has completed, sponsored by Ciphergen Biosystems.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 18
- Study locations
Study Summary
Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed. It has been shown that women with ovarian cancer who are referred to gynecologic oncologists have better outcomes. The primary objective of this study is to demonstrate that the OvaRl assay (test) improves the preoperative identification of ovarian cancer in patients with a ovarian tumor.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (18)
Arizona
- Women's Health Research - Phoenix
- Precision Trials - Phoenix
California
- Gynecologic Oncology Associates - Newport Beach
- North Coast Women's Care Medical Group Inc - Vista
Connecticut
- Farmington Obstetrics and Gynecology Group - Avon
- The GYN Center for Women's Health - Waterbury
Florida
- Florida Hospital Cancer Institute - Orlando
- OB/GYN Specialists of the Palm Beaches - West Palm Beach
Texas
- SWRCC - Austin
- UT South Western Medical Center at Dallas - Dallas
Alabama
- Clinical Research Consultants - Hoover
Kentucky
- University of Kentucky - Whitney Facility - Lexington
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436189
The ClinicalTrials.gov registry entry for NCT00436189 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The listed sponsor is Ciphergen Biosystems, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Tumor appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT00436189 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00436189 about?
NCT00436189 is a clinical study titled "Assess Cancer in Ovarian Tumors With Biomarkers.". Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed....
What is the current status of trial NCT00436189?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2007-02. Estimated completion is 2008-04.
What conditions does trial NCT00436189 study?
This clinical trial studies the following conditions: Ovarian Tumor.
What interventions are being tested in trial NCT00436189?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT00436189?
This trial is sponsored by Ciphergen Biosystems, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00436189 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.